Ozempic Price Cut: Novo's $675 List Price Adds a Third Number

What Novo announced

Novo Nordisk says it will reset the U.S. list price of its three semaglutide drugs, Ozempic, Wegovy and Rybelsus, to a flat $675 for a month's supply starting January 1, 2027. 13 For injectable and oral Wegovy, now listed at $1,349.02, that is roughly a 50% cut. Ozempic and Rybelsus, both currently at $1,027.51, fall by about 34%. 1

The company describes the move as a way to widen access. Jamey Millar, who leads Novo's U.S. operations, said lower list prices are the best way to reach the more than 100 million Americans with obesity and over 35 million with type 2 diabetes. He added that public and private payers and patients have been pushing for the change. 1

The headline number suggests broad relief. The fine print is narrower.

Who actually saves

The cut applies to the list price, the sticker figure that sits upstream of rebates and negotiated discounts. Novo officials said the goal is to help insured patients whose costs are tied to that list price. 3 In practice, that means people paying coinsurance, a percentage of the drug's price, and people in high-deductible plans who pay full freight until they meet their deductible. 23

Cash-pay customers are left out. The reduction will not change what consumers pay when they buy these drugs outside insurance. 3 Patients with flat copays may also see little difference, since their out-of-pocket amount doesn't scale with list price. That is my inference from how such plans are structured, not something Novo has spelled out.

Three prices for the same molecule

The bigger source of confusion is that $675 is not the only 2027 figure attached to these drugs. 2

$274 under the Inflation Reduction Act. Ozempic and Wegovy were among the 15 Part D drugs in the second round of Medicare price negotiation. On November 25, 2025, CMS announced "maximum fair prices" for that group. 5 For semaglutide, the agency set $274 for a 30-day supply, a 71% discount from list, effective January 2027. 4 CMS projects the full slate of 15 drugs will save Medicare about $12 billion in net drug costs and save beneficiaries an estimated $685 million out of pocket under the standard Part D benefit. 5 The $274 figure is what Medicare pays the manufacturer, not what a beneficiary pays at the counter. It also has no bearing on commercial insurance, Medicaid or cash prices. 2

$245 under a Trump administration deal. A separate "most-favored-nation" arrangement puts a $245 monthly figure in play for Medicare as well, and it may supersede the negotiated $274. 2 It fits a broader White House push that includes an April 15, 2025 executive order. That order aims to "improve" the IRA, test new payment models for high-cost drugs, streamline importation and use tariffs to pressure manufacturers into building U.S. plants. 5

The result is one molecule with three overlapping 2027 prices, each covering a different slice of the market. Coverage of the announcement has largely treated these as one story, which helps explain why patients may expect savings that won't arrive. 2

The competitive backdrop

Policy is only part of the picture. Novo faces heavy competition from Eli Lilly, whose obesity drug Zepbound has been taking a growing share of the market. 3 Cutting list price makes Novo's products more attractive to employers and insurers designing benefits. It also lands at a moment when Medicare's own prices will soon sit far below the old list price anyway.

The next phase of competition may be shaped by how drugs are regulated. Lilly has sought biologic status for its experimental drug retatrutide. 4 Under the IRA, drugs approved as small molecules become eligible for Medicare negotiation after 7 years, compared with 11 years for biologics. Negotiated prices take effect roughly 9 and 13 years after approval, respectively. 4 Lilly began pursuing the designation in November 2023, three months after CMS named its first negotiation picks. A biologic classification would give retatrutide four extra years before facing the kind of pressure semaglutide now faces. 4

The takeaway

Novo's cut is real, but it is a targeted adjustment rather than a universal discount. It helps insured patients whose costs track list price. It does nothing for cash buyers. And it sits alongside two lower Medicare figures that apply only to that program. 23

My reading is that the move is partly defensive. It narrows the gap between list and net prices ahead of government-set rates and keeps Novo competitive with Lilly in commercial coverage. For patients, the useful question is not "what does Ozempic cost?" but "which of the three prices applies to my plan?"